Market Cap : 41.99 B | Enterprise Value : 43.61 B | PE Ratio : 14.85 | PB Ratio : 3.29 |
---|
BIIB has been successfully added to your Stock Email Alerts list.
You can manage your stock email alerts here.
BIIB has been removed from your Stock Email Alerts list.
Please enter Portfolio Name for new portfolio.
Asset Turnover measures how quickly a company turns over its asset through sales. It is calculated as Revenue divided by Total Assets. Biogen's Revenue for the three months ended in Sep. 2022 was $2,509 Mil. Biogen's Total Assets for the quarter that ended in Sep. 2022 was $24,968 Mil. Therefore, Biogen's Asset Turnover for the quarter that ended in Sep. 2022 was 0.10.
Asset Turnover is linked to ROE % through Du Pont Formula. Biogen's annualized ROE % for the quarter that ended in Sep. 2022 was 36.83%. It is also linked to ROA % through Du Pont Formula. Biogen's annualized ROA % for the quarter that ended in Sep. 2022 was 18.18%.
The historical data trend for Biogen's Asset Turnover can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Drug Manufacturers - General subindustry, Biogen's Asset Turnover, along with its competitors' market caps and Asset Turnover data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
For the Drug Manufacturers industry and Healthcare sector, Biogen's Asset Turnover distribution charts can be found below:
* The bar in red indicates where Biogen's Asset Turnover falls in comparison to its industry or sector. The grey bar indicates the Asset Turnover's extreme value range as defined by GuruFocus.
Asset Turnover measures how quickly a company turns over its asset through sales.
Biogen's Asset Turnover for the fiscal year that ended in Dec. 2021 is calculated as
Asset Turnover | ||||||
= | Revenue | / | Average Total Assets | |||
= | Revenue (A: Dec. 2021 ) | / | ( (Total Assets (A: Dec. 2020 ) | + | Total Assets (A: Dec. 2021 )) | / count ) |
= | 10981.7 | / | ( (24618.9 | + | 23877.3) | / 2 ) |
= | 10981.7 | / | 24248.1 | |||
= | 0.45 |
Biogen's Asset Turnover for the quarter that ended in Sep. 2022 is calculated as
Asset Turnover | ||||||
= | Revenue | / | Average Total Assets | |||
= | Revenue (Q: Sep. 2022 ) | / | ( (Total Assets (Q: Jun. 2022 ) | + | Total Assets (Q: Sep. 2022 )) | / count ) |
= | 2508.5 | / | ( (25081.4 | + | 24854.2) | / 2 ) |
= | 2508.5 | / | 24967.8 | |||
= | 0.10 |
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Companies with low profit margins tend to have high Asset Turnover, while those with high profit margins have low Asset Turnover. Companies in the retail industry tend to have a very high turnover ratio.
Asset Turnover is linked to ROE % through Du Pont Formula.
Biogen's annulized ROE % for the quarter that ended in Sep. 2022 is
ROE %** | (Q: Sep. 2022 ) | ||||
= | Net Income | / | Total Stockholders Equity | ||
= | 4538.8 | / | 12324 | ||
= | (Net Income / Revenue) | * | (Revenue / Total Assets) | * | (Total Assets / Total Stockholders Equity) |
= | (4538.8 / 10034) | * | (10034 / 24967.8) | * | (24967.8/ 12324) |
= | Net Margin % | * | Asset Turnover | * | Equity Multiplier |
= | 45.23 % | * | 0.4019 | * | 2.0259 |
= | ROA % | * | Equity Multiplier | ||
= | 18.18 % | * | 2.0259 | ||
= | 36.83 % |
Note: The Net Income data used here is four times the quarterly (Sep. 2022) net income data. The Revenue data used here is four times the quarterly (Sep. 2022) revenue data.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
** The ROE % used above is for Du Pont Analysis only. It is different from the defined ROE % page on our website, as here it uses Net Income instead of Net Income attributable to Common Stockholders in the calculation.
It is also linked to ROA % through Du Pont Formula:
Biogen's annulized ROA % for the quarter that ended in Sep. 2022 is
ROA % | (Q: Sep. 2022 ) | ||
= | Net Income | / | Total Assets |
= | 4538.8 | / | 24967.8 |
= | (Net Income / Revenue) | * | (Revenue / Total Assets) |
= | (4538.8 / 10034) | * | (10034 / 24967.8) |
= | Net Margin % | * | Asset Turnover |
= | 45.23 % | * | 0.4019 |
= | 18.18 % |
Note: The Net Income data used here is four times the quarterly (Sep. 2022) net income data. The Revenue data used here is four times the quarterly (Sep. 2022) revenue data.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
In the article Joining The Dark Side: Pirates, Spies and Short Sellers, James Montier reported that In their US sample covering the period 1968-2003, Cooper et al find that firms with low asset growth outperformed firms with high asset growth by an astounding 20% p.a. equally weighted. Even when controlling for market, size and style, low asset growth firms outperformed high asset growth firms by 13% p.a. Therefore a company with fast asset growth may underperform.
Therefore, it is a good sign if a company's Asset Turnover is consistent or even increases. If a company's asset grows faster than sales, its Asset Turnover will decline, which can be a warning sign.
Thank you for viewing the detailed overview of Biogen's Asset Turnover provided by GuruFocus.com. Please click on the following links to see related term pages.
Christopher Viehbacher | director, officer: President and CEO | C/O AXCELLA HEALTH, INC., 840 MEMORIAL DRIVE, CAMBRIDGE MA 02139 |
Nicole Murphy | officer: Head of Pharm Ops and Tech | BIOGEN INC., 225 BINNEY STREET, CAMBRIDGE MA 02142 |
Rachid Izzar | officer: Head of Alzheimer's Disease | BIOGEN INC., 225 BINNEY STREET, CAMBRIDGE MA 02142 |
Jones William D /ca/ | director | |
Maria C Freire | director | C/O ALEXANDRIA REAL ESTATE EQUITIES, INC, 26 NORTH EUCLID AVENUE, PASADENA CA 91101 |
Michael R Mcdonnell | officer: EVP, Chief Financial Officer | C/O IQVIA HOLDINGS INC., 83 WOOSTER HEIGHTS ROAD, DANBURY CT 06810 |
Alphonse Galdes | officer: EVP Pharmaceutical Oper & Tech | BIOGEN INC., 225 BINNEY ST., CAMBRIDGE MA 02142 |
William A Hawkins | director | MEDTRONIC INC, 710 MEDTRONIC PKWY, MS LC310, MINNEAPOLIS MN 55432-5604 |
Jesus B Mantas | director | BIOGEN INC., 225 BINNEY STREET, CAMBRIDGE MA 02142 |
Robin Kramer | officer: VP, Chief Accounting Officer | 999 VANDERBILT BEACH ROAD, 3RD FLOOR, NAPLES FL 34109 |
Daniel Karp | officer: EVP, Corporate Development | 225 BINNEY STREET, CAMBRIDGE MA 02142 |
Jeffrey D Capello | officer: EVP & Chief Financial Officer | C/O NEOGEN CORP., 620 LESHER PLACE, LANSING MI 48912 |
Chirfi Guindo | officer: EVP Glob. Mkt Acc & Cust Innov | C/O BIOGEN INC., 225 BINNEY ST., CAMBRIDGE MA 02142 |
Ginger Gregory | officer: EVP, Human Resources | C/O BIOGEN INC., 225 BINNEY ST., CAMBRIDGE MA 02142 |
Jean-paul Kress | officer: EVP Pres Int'l & Global Hd GTO | 215 FIRST STREET, SUITE 415, CAMBRIDGE MA 02142 |
From GuruFocus
By Stock market mentor 01-04-2023
By Business Wire 11-17-2022
By PRNewswire 01-27-2023
By Value_Insider 10-26-2022
By Stock market mentor 01-27-2023
By PRNewswire 01-06-2023
By Value_Insider 12-09-2022
Other Sources
By Yahoo Finance 2023-01-27
By Zacks 2023-01-23
By Reuters 2023-01-25
By Yahoo Finance 2023-01-26
By CNBC 2023-01-20
By Yahoo Finance 2023-01-26
By Zacks 2023-01-30
By Zacks 2023-01-27
By Reuters 2023-01-26
By Yahoo Finance 2023-01-20
By Yahoo Finance 2023-01-24
By Zacks 2023-01-27
By Yahoo Finance 2023-01-30
By Yahoo Finance 2023-01-20
By Yahoo Finance 2023-01-25